# Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response

> **NCT03341429** · PHASE4 · COMPLETED · sponsor: **University College, London** · enrollment: 70 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Liraglutide Pen Injector [Saxenda]
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03341429
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-22
- **Primary completion:** 2019-11-28
- **Final completion:** 2020-06-11
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2020-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03341429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03341429, "Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT03341429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*